KLOW peptide: four chemically distinct research arms, one co-formulated vial, zero controlled blend studies on record.

The short version

KLOW peptide is a research blend that combines four different peptides in one vial: KPV, GHK-Cu, BPC-157, and TB-500. Each one has its own body of published science — animal studies, cell experiments, and in some cases limited human data. The idea behind combining them is that they target different steps in the body's repair and recovery process: KPV dials down inflammation, GHK-Cu supports collagen and skin-repair biology, BPC-157 promotes new blood-vessel growth in damaged tissue, and TB-500 is tied to cell movement and wound closure.

The important caveat: no study has ever tested these four peptides together. Every claim about what KLOW does as a blend is an extrapolation from the separate component studies. On top of that, the four peptides don't stay in the body for the same length of time — the smaller KPV and GHK-Cu clear out quickly while BPC-157 lingers longer — which is a practical complication a single mixed vial cannot fully solve.

None of the four peptides is FDA-approved. The blend is not a weight-loss compound. TB-500 is banned in sport (WADA S2). What people report about using it — and what to watch out for — is on the KLOW effects page.

KLOW peptide: compound identity and vial composition

KLOW peptide is a co-formulated lyophilized blend of four chemically distinct research peptides. The most widely listed research-vial composition is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg — a 5:1:1:1 mass ratio in which GHK-Cu is the dominant component at approximately 62.5% of the vial. No single chemical entity or approved pharmacopeial KLOW combination product exists; the peptides are co-dissolved but remain separate molecules.

The four components address mechanistically non-overlapping nodes of the same tissue-repair and inflammatory-resolution cascade: NF-kappaB (a transcription factor central to inflammatory gene expression) suppression by KPV via the PepT1 intestinal transporter, extracellular-matrix remodeling and transcriptomic reprogramming by GHK-Cu (Copper Tripeptide-1), VEGFR2-driven angiogenesis (vascular endothelial growth factor receptor 2 — the primary receptor that signals new blood-vessel formation) by BPC-157, and G-actin sequestration (binding monomeric actin to regulate cell migration) by the TB-500 / thymosin beta-4 arm. This mechanistic complementarity is the rationale for the combination.

The combination rationale has not been tested experimentally. Every in-vivo efficacy claim for KLOW-as-a-blend is an extrapolation from the single-component literature.

KLOW blend pharmacokinetics: the structural mismatch

The dealt angle for this domain is pharmacokinetics-delivery, because the blend's most significant under-documented structural feature is a pharmacokinetic (PK) mismatch among its four arms. Pharmacokinetics describes how quickly a compound is absorbed, distributed, and cleared from the body.

The two tripeptides — KPV (MW 342.44 Da, CAS 67727-97-3) and GHK-Cu (MW 402.92 Da, CAS 89030-95-5) — are subject to rapid peptidase clearance; rat plasma data for GHK document prompt degradation to the dipeptide histidyl-lysine after intravenous administration ^[8]. BPC-157 (MW 1419.53 Da, CAS 137525-51-0), at roughly three to four times the molecular weight of the tripeptides, has an elimination half-life of under approximately 30 minutes in rat pharmacokinetic studies. TB-500 (Ac-LKKTETQ, MW 889.02 Da) is the synthetic heptapeptide fragment corresponding to the actin-binding motif of native thymosin beta-4; its PK in humans has not been characterized, and the fragment behaves differently from the full-length 43-amino-acid native protein on which most efficacy data rest ^[9].

The practical consequence: a single co-formulated dose of KLOW cannot keep all four components at matched tissue exposures simultaneously. The faster-clearing tripeptides reach their peak and fall before the slower-clearing BPC-157 has completed its window. No controlled study has characterized whether this matters clinically; the mismatch is a structural property of the blend, documented here because it is essential to interpreting any research-derived dosing context. The absence of controlled blend data on PK is logged as the structural blank it is.

What the component literature records

KPV (anti-inflammatory arm). In human intestinal epithelial cells and murine colitis models, nanomolar KPV inhibits NF-kappaB and MAPK (ERK/p38) inflammatory signaling and reduces TNF-alpha, IL-6, and IL-1beta output; uptake is PepT1 (SLC15A1)-mediated with a Km of approximately 160 microM, meaning inflamed gut mucosa (where PepT1 is upregulated) has a selective uptake advantage ^[3]. Hyaluronic-acid-functionalized nanoparticle carriers of KPV showed improved colonic delivery and reduced mucosal damage in DSS-induced murine colitis versus non-targeted formulations ^[11]. A 2026 study demonstrated self-immolative conjugates that improved oral bioavailability of peptides across the intestinal barrier, directly addressing the core delivery challenge for oral KPV-class compounds ^[15].

GHK-Cu (matrix-and-copper arm). Pickart's 2015 review established GHK-Cu as a collagen, dermatan sulfate, and proteoglycan inducer; endogenous plasma GHK falls from ~200 ng/mL at age 20 to ~80 ng/mL by age 60, and topical GHK-Cu outperformed vitamin C and retinoic acid in a placebo-controlled collagen-production measure ^[4]. A 2018 Connectivity Map analysis showed GHK modulates approximately 31.2% of human genes at a 50%-or-greater change threshold, with strong signals on DNA repair, antioxidant gene sets, and the ubiquitin-proteasome system ^[5]. Human ex-vivo skin penetration studies quantify a transdermal copper depot of 97 ± 6.6 microg/cm^2 at 48 h ^[10], confirming topical delivery is viable for the copper arm.

BPC-157 (angiogenic arm). BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures, and stimulated tendocyte outgrowth in vitro ^[2]. Separately, fistula resolution in a rat model linked BPC-157 activity to the nitric-oxide system ^[14], extending the documented tissue-repair mechanism beyond the VEGFR2/PI3K/Akt/eNOS angiogenic axis. A 2025 first-in-human IV pilot found intravenous BPC-157 at up to 20 mg was well tolerated in two adults with no observed adverse events and no changes in safety biomarkers ^[6].

TB-500 / thymosin beta-4 (cytoskeletal arm). In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and 61% at 7 days versus saline, increased wound contraction (≥11% by day 7), and raised collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration 2–3-fold ^[1]. Critically, this is native thymosin beta-4 data. The TB-500 fragment (Ac-LKKTETQ) was characterized as a doping analyte for sport, not yet as a distinct clinical entity ^[9]. A 2026 Sports Medicine review notes favorable animal outcomes for unapproved musculoskeletal peptides including TB-500 and BPC-157, but scarce human safety data ^[7].

See KLOW research for the full mechanism and study registry.

Record status

No controlled blend trial on record. Zero controlled in-vivo or human studies have tested the four-peptide KLOW combination against monotherapy, any subset, or placebo. The zero-trial status is a structural feature of this literature record, not an editorial omission.

TB-500 and WADA status. TB-500 / thymosin beta-4 is listed on the WADA Prohibited List under S2 (peptide hormones, growth factors, related substances, and mimetics), banned at all times. The blend therefore implicates anti-doping rules in any athletic-research context. See KLOW effects for the full safety specification.

This record is compiled from the peer-reviewed primary literature. Citations index to KLOW references.